Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.

Completed · Phase 2

Conditions studied: Dyslipidemia

In brief

To assess the effect of CP-778,875 on HDL-C cholesterol in adult subjects with dyslipidemia and type 2 diabetes

Key facts

Study ID

NCT00326326

Run by

Pfizer

People needed

84

Starts

2006-07-01

Expected to finish

2007-06-01

Last updated by the study team

2009-05-07

Who can join

Age: 30 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HDL-C < or = 45 mg/dL for men and < or = 55 mg/dL for women
• Triglycerides between 150-500 mg/dL
• Fasting Plasma Glucose 140-240 mg/dL

You may not qualify if…

• Known cardiovascular, carotid, or peripheral vascular disease

Where it is running

• Pfizer Investigational Site — Anniston, Alabama, United States
• Pfizer Investigational Site — Huntsville, Alabama, United States
• Pfizer Investigational Site — Greenbrae, California, United States
• Pfizer Investigational Site — Los Angeles, California, United States
• Pfizer Investigational Site — Walnut Creek, California, United States
• Pfizer Investigational Site — DeFuniak Springs, Florida, United States
• Pfizer Investigational Site — Destin, Florida, United States
• Pfizer Investigational Site — Jupiter, Florida, United States
• Pfizer Investigational Site — Melbourne, Florida, United States
• Pfizer Investigational Site — Atlanta, Georgia, United States
• Pfizer Investigational Site — Conyers, Georgia, United States
• Pfizer Investigational Site — Chicago, Illinois, United States
• Pfizer Investigational Site — Iowa City, Iowa, United States
• Pfizer Investigational Site — Lexington, Kentucky, United States
• Pfizer Investigational Site — Baltimore, Maryland, United States
• Pfizer Investigational Site — Springfield, Missouri, United States
• Pfizer Investigational Site — Omaha, Nebraska, United States
• Pfizer Investigational Site — Las Vegas, Nevada, United States
• Pfizer Investigational Site — Mount Vernon, New York, United States
• Pfizer Investigational Site — Oklahoma City, Oklahoma, United States
• Pfizer Investigational Site — Tulsa, Oklahoma, United States
• Pfizer Investigational Site — Kingsport, Tennessee, United States
• Pfizer Investigational Site — Bryan, Texas, United States
• Pfizer Investigational Site — Houston, Texas, United States
• Pfizer Investigational Site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.